Drug Profile
D 086
Alternative Names: D086Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Antihyperlipidaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperlipidaemia; Hypertension
Most Recent Events
- 07 Dec 2022 No development reported - Phase-III for Hypertension (Combination therapy) in South Korea (PO)
- 22 Jul 2020 Chong Kun Dang Pharmaceutical plans a phase I trial for Cardiovascular disorders (In volunteers, Combination therapy) (co-administered with CKD 330) in South Korea (PO) (NCT04478097)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Hyperlipidaemia(Combination therapy, In volunteers) in South Korea (PO, Tablet)